Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Multiple myeloma treatments within the elderly population

Elizabeth O'Donnell • 13 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Daratumumab Dexamethasone Ixazomib Lenalidomide
MAIA

Elizabeth O’Donnell, MD Massachusetts General Hospital, Boston, MA, speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA, discusses developments within the treatment of the elderly population for multiple myeloma. O’Donnell advocates for triplet therapy over doublet therapy, and suggests alternative paths forward in elderly patient treatment.

More from Elizabeth O'Donnell

SMM & MGUS: clinical relevance, the PROMISE study & the role of genomics
Elizabeth O'Donnell et al. • 25 Mar 2024
2:04
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma: the SKylaRk trial
Elizabeth O'Donnell • 11 Dec 2023
0:50
Tools to improve frailty assessment in patients with multiple myeloma
Elizabeth O'Donnell • 28 Sep 2023
1:02
Tailoring therapy for patients with multiple myeloma to improve outcomes
Elizabeth O'Donnell • 28 Sep 2023

Related Videos

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals